STRS Ohio’s Travere Therapeutics TVTX Stock Holding History

STRS Ohio’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Buy	+6,600	New	+$293K	﹤0.01%	1292
2021 Q2	–	Sell	-4,600	Closed	-$114K	–	2433
2021 Q1	$114K	Hold	4,600	–	–	﹤0.01%	1918
2020 Q4	$125K	Buy	+4,600	New	+$107K	﹤0.01%	1849
2020 Q3	–	Sell	-4,600	Closed	-$93K	–	2280
2020 Q2	$93K	Hold	4,600	–	–	﹤0.01%	1807
2020 Q1	$67K	Hold	4,600	–	–	﹤0.01%	1746
2019 Q4	$65K	Sell	4,600 -30,100	-87%	-$384K	﹤0.01%	1852
2019 Q3	$402K	Hold	34,700	–	–	﹤0.01%	1407
2019 Q2	$697K	Buy	34,700 +2,400	+7%	+$47.4K	﹤0.01%	1016
2019 Q1	$730K	Hold	32,300	–	–	﹤0.01%	982
2018 Q4	$730K	Hold	32,300	–	–	﹤0.01%	936
2018 Q3	$927K	Sell	32,300 -2,600	-7%	-$74.3K	﹤0.01%	918
2018 Q2	$951K	Sell	34,900 -900	-3%	-$24K	﹤0.01%	924
2018 Q1	$800K	Sell	35,800 -3,300	-8%	-$78.6K	﹤0.01%	1009
2017 Q4	$823K	Buy	39,100 +2,600	+7%	+$59.4K	﹤0.01%	971
2017 Q3	$908K	Buy	+36,500	New	+$804K	﹤0.01%	919

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

STRS Ohio's TVTX Position: Q2 2026 in Review

STRS Ohio opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 6,600 shares worth $375K. The stake represents ﹤0.01% of the portfolio and ranks #1292 among its holdings. This is a return to the name: STRS Ohio previously reported a position in TVTX as recently as Q1 2021.

STRS Ohio first reported a position in TVTX in Q3 2017 and has held it in 15 quarters since. The position peaked at $951K in Q2 2018. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

STRS Ohio held 6,600 shares of Travere Therapeutics worth $375K as of Q2 2026.
Travere Therapeutics was a new STRS Ohio position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1292 holding.
STRS Ohio first reported a position in Travere Therapeutics in Q3 2017 and has held it in 15 quarters since.
STRS Ohio's Travere Therapeutics position peaked at $951K in Q2 2018.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.